Trial Profile
A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK6186 in HIV-1 Infected Patients
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs MK 6186 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Jul 2011 Planned End Date changed from 1 Oct 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 13 May 2011 Planned End Date changed from 1 Mar 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.